REGENXBIO (RGNX) Expected to Post Quarterly Earnings on Thursday

Key Points

• REGENXBIO is expected to report Q3 2026 results before the market opens on November 5. Analysts forecast a loss of $1.30 per share and revenue of approximately $14.88 million.
• In the prior quarter, the biotechnology company reported $0.43 in EPS, beating estimates of $0.08, while revenue of $108.02 million also exceeded expectations.
• Analyst sentiment is moderately bullish: REGENXBIO has an average “Moderate Buy” rating and a consensus price target of $23.17, well above its recent share price of $7.24.

REGENXBIO (NASDAQ:RGNX - Get Free Report) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect REGENXBIO to post earnings of ($1.2981) per share and revenue of $14.88 million for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.35. REGENXBIO had a negative net margin of 112.58% and a negative return on equity of 220.07%. The company had revenue of $108.02 million for the quarter, compared to analyst estimates of $97.63 million. On average, analysts expect REGENXBIO to post ($3.70) EPS for the current fiscal year and ($2.94) EPS for the next fiscal year.

REGENXBIO Stock Performance

Shares of NASDAQ:RGNX opened at $7.24 on Thursday. REGENXBIO has a one year low of $5.45 and a one year high of $16.19. The stock has a market capitalization of $477.91 million, a price-to-earnings ratio of -1.91 and a beta of 1.13. The company has a 50-day simple moving average of $8.15 and a 200-day simple moving average of $9.30.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on RGNX. Zacks Research upgraded REGENXBIO from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 12th. Morgan Stanley reaffirmed an "overweight" rating and set a $18.00 price objective on shares of REGENXBIO in a research note on Friday, August 7th. Wall Street Zen raised REGENXBIO from a "strong sell" rating to a "hold" rating in a research report on Saturday, August 8th. HC Wainwright reiterated a "buy" rating on shares of REGENXBIO in a research note on Monday, September 28th. Finally, Mizuho began coverage on REGENXBIO in a research note on Monday, October 5th. They issued an "outperform" rating and a $22.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $23.17.

REGENXBIO Company Profile

REGENXBIO Inc NASDAQ: RGNX is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company's programs use adeno-associated virus (AAV) vectors to deliver genetic material to targeted cells, with the goal of addressing the underlying causes of disease rather than primarily treating symptoms.

REGENXBIO's technology is built around its NAV AAV Technology Platform, which supports the design and development of gene-delivery vectors. Its pipeline has included investigational therapies for conditions such as Duchenne muscular dystrophy, Hunter syndrome, age-related macular degeneration and other rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.